Tsay J T, Rock C O, Jackowski S
Department of Biochemistry, St. Jude Children's Research Hospital, Memphis, Tennessee 38101.
J Bacteriol. 1992 Jan;174(2):508-13. doi: 10.1128/jb.174.2.508-513.1992.
Thiolactomycin [(4S)(2E,5E)-2,4,6-trimethyl-3-hydroxy-2,5,7-octatriene- 4-thiolide] (TLM) is a unique antibiotic structure that inhibits dissociated type II fatty acid synthase systems but not the multifunctional type I fatty acid synthases found in mammals. We screened an Escherichia coli genomic library for recombinant plasmids that impart TLM resistance to a TLM-sensitive strain of E. coli K-12. Nine independent plasmids were isolated, and all possessed a functional beta-ketoacyl-acyl carrier protein synthase I gene (fabB) based on their restriction enzyme maps and complementation of the temperature-sensitive growth of a fabB15(Ts) mutant. A plasmid (pJTB3) was constructed that contained only the fabB open reading frame. This plasmid conferred TLM resistance, complemented the fabB(Ts) mutation, and directed the overproduction of synthase I activity. TLM selectively inhibited unsaturated fatty acid synthesis in vivo; however, synthase I was not the only TLM target, since supplementation with oleate to circumvent the cellular requirement for an active synthase I did not confer TLM resistance. Overproduction of the FabB protein resulted in TLM-resistant fatty acid biosynthesis in vivo and in vitro. These data show that beta-ketoacyl-acyl carrier protein synthase I is a major target for TLM and that increased expression of this condensing enzyme is one mechanism for acquiring TLM resistance. However, extracts from a TLM-resistant mutant (strain CDM5) contained normal levels of TLM-sensitive synthase I activity, illustrating that there are other mechanisms of TLM resistance.
硫内酯霉素[(4S)(2E,5E)-2,4,6-三甲基-3-羟基-2,5,7-辛三烯-4-硫代内酯](TLM)是一种独特的抗生素结构,它能抑制解离型II脂肪酸合酶系统,但不抑制哺乳动物中发现的多功能I型脂肪酸合酶。我们在大肠杆菌基因组文库中筛选了能赋予对TLM敏感的大肠杆菌K-12菌株TLM抗性的重组质粒。分离出了9个独立的质粒,根据其限制性酶切图谱以及对fabB15(Ts)突变体温度敏感生长的互补作用,所有这些质粒都含有一个功能性的β-酮酰基-酰基载体蛋白合酶I基因(fabB)。构建了一个仅包含fabB开放阅读框的质粒(pJTB3)。该质粒赋予了TLM抗性,互补了fabB(Ts)突变,并指导了合酶I活性的过量产生。TLM在体内选择性地抑制不饱和脂肪酸的合成;然而,合酶I并不是TLM的唯一靶点,因为补充油酸以规避细胞对活性合酶I的需求并不能赋予TLM抗性。FabB蛋白的过量产生导致体内和体外对TLM抗性的脂肪酸生物合成。这些数据表明β-酮酰基-酰基载体蛋白合酶I是TLM的主要靶点,并且这种缩合酶表达的增加是获得TLM抗性的一种机制。然而,来自TLM抗性突变体(CDM5菌株)的提取物含有正常水平的对TLM敏感的合酶I活性,这说明存在其他的TLM抗性机制。